Incannex is developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnea, rheumatoid arthritis and generalized anxiety disorder. Each of these products are currently undergoing clinical development and are not available outside of clinical trials. The contribution of trial participants is critical to the development of Incannex’s drug products. If you are interested in enrolling in one of Incannex’s clinical trials, please see the open trials listed on clinicaltrials.gov.
Incannex is dedicated to developing and delivering innovative medicines for people living with chronic diseases and significant unmet needs. To ensure the safety, efficacy, and quality of these therapies, we are dedicated to conducting rigorous, large-scale clinical trials that generate the robust data required to support regulatory approvals by the U.S. Food and Drug Administration (FDA) and other global regulatory authorities.
Access to Incannex’s investigational therapies is currently limited to those participating in our clinical trials. This approach allows us to maintain the rigorous oversight necessary to ensure patient safety, while advancing the development of our innovative therapeutics in the most effective and expedient manner possible.
Expanded Access, sometimes referred to as “compassionate use,” is a mechanism that allows patients with serious or life-threatening conditions to access investigational therapies outside of clinical trials. While Incannex recognizes the importance of Expanded Access programs, we currently do not provide investigational therapies through such pathways. We believe that participation in clinical trials remains the most appropriate and equitable means of accessing our investigational therapies at this stage of development.
We are continuously evaluating the feasibility of Expanded Access programs and will adjust our policies, as appropriate, consistent with applicable regulatory guidelines and ethical considerations.
We encourage physicians and patients interested in our investigational therapies to review our ongoing clinical studies by visiting clinicaltrials.gov. Physicians interested in collaborating on clinical trials, or learning more about our investigational therapies may contact us directly.
IHL-42X is our investigational drug currently in Phase 2 clinical development for the treatment of obstructive sleep apnea (OSA). We are conducting the study in the U.S. to evaluate the safety and efficacy of IHL-42X in adults with OSA who have tried CPAP/PAP but do not use it regularly, cannot tolerate it, or have chosen not to use it after discussing treatment with their doctor.
IHL-42X
Obstructive Sleep Apnea (OSA)
Trial Title: DReAMzz- Dronabinol and Acetazolamide Medication for Sleep Apnea (ZZ). Dose Confirmation Crossover Study for IHL-42X in Subjects With Obstructive Sleep Apnea.
Trial Number: NCT07635563
Stage: Phase 2
Status: Recruiting
To learn more about the clinical trial and study sites, please visit: https://dreamzztrial.com/

IHL-42X is an oral fixed-dose combination therapy of acetazolamide and dronabinol currently in clinical studies for the treatment of obstructive sleep apnea (OSA).
IHL-675A is an oral fixed-dose combination of a synthetic cannabidiol and hydroxychloroquine sulfate (HCQ) that is currently in Phase 2 development for the treatment of rheumatoid arthritis (RA).
PSX-001 is an oral synthetic psilocybin currently being studied in combination with psychological support as a treatment for adults with generalized anxiety disorder (GAD).